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NEOPLASIA
Evidence for position effects as a variant ETV6-mediated leukemogenic
mechanism in myeloid leukemias with a t(4;12)(q11-q12;p13) or t(5;12)(q31;p13)
Jan Cools, Nicole Mentens, Maria D. Odero, Pieter Peeters, Iwona Wlodarska, Michel Delforge, Anne Hagemeijer, and Peter Marynen
The ETV6 gene (first identified as TEL) is
a frequent target of chromosomal translo-
cations in both myeloid and lymphoid
leukemias. At present, more than 40 dis-
tinct translocations have been cytogeneti-
cally described, of which 13 have now
also been characterized at the molecular
level. These studies revealed the genera-
tion of in-frame fusion genes between
different domains of ETV6 and partner
genes encoding either kinases or tran-
scription factors. However, in a number of
cases—including a t(6;12)(q23;p13), the
recurrent t(5;12)(q31;p13), and some
cases of the t(4;12)(q11-q12;p13) de-
scribed in this work—functionally signifi-
cant fusions could not be identified, rais-
ing the question as to what leukemogenic
mechanism is implicated in these cases.
To investigate this, we have evaluated the
genomic regions at 4q11-q12 and 5q31,
telomeric to the breakpoints of the t(4;
12)(q11-q12;p13) and t(5;12)(q31;p13). The
homeobox gene GSH2 at 4q11-q12 and
the IL-3/CSF2 locus at 5q31 were found to
be located close to the respective break-
points. In addition, GSH2 and IL-3 were
found to be ectopically expressed in the
leukemic cells, suggesting that expres-
sion of GSH2 and IL-3 was deregulated by
the translocation. Our results indicate
that, besides the generation of fusion
transcripts, deregulation of the expres-
sion of oncogenes could be a variant
leukemogenic mechanism for transloca-
tions involving the 5* end of ETV6, espe-
cially for those translocations lacking
functionally significant fusion transcripts.
(Blood. 2002;99:1776-1784)
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Introduction
Cytogenetic and molecular characterization has demonstrated that
nonrandom chromosomal rearrangements in hematologic malignan-
cies are associated with specific oncogenic mechanisms.1,2 Translo-
cations and inversions can result in the generation of oncogenic
fusion genes or deregulated expression of protooncogenes.1,2 The
latter mechanism has been mainly described for translocations and
inversions involving the immunoglobulin heavy and light chain
(IgH/L) loci or T-cell receptor (TCR) loci in lymphoid leukemias
and lymphomas. In these cases, expression of protooncogenes is
deregulated by their juxtaposition to, respectively, B-cell– or
T-cell–specific regulatory sequences of the IgH/L or TCR loci.2
This mechanism is less common in myeloid leukemias, although
some examples, such as the inv (3)(q21q26) with RPN1-mediated
ectopic expression of EVI1, have been described.3,4 The other
mechanism, the generation of oncogenic fusion proteins, is ob-
served in both lymphoid and myeloid malignancies and frequently
involves the CBFA2 (21q22), MLL (11q23), and ETV6 (12p13) loci,
which are known to be fused to a wide variety of partner genes.5
Translocations involving the ETV6 gene are among the most
intriguing aberrations found in hematologic malignancies, not only
because so many different translocation partners—more than
405,6—have been cytogenetically described, but also because this
gene contributes to leukemogenesis through at least 3 different
mechanisms. One mechanism is the modulation of the activity of
the transcription factors such as CBFA2 and ARNT or the
activation of the kinases PDGFRB, ABL1, ABL2, JAK2, NTRK3,
and SYK by the generation of a fusion protein including the
homodimerization (pointed) domain of ETV6.7-16 A second mecha-
nism is found in the MN1-ETV6 fusion protein that contains the
DNA binding domain of ETV617 and was recently demonstrated to
function as a chimeric transcription factor with oncogenic proper-
ties.18 Finally, the ETV6-MDS1/EVI1 and ETV6-CDX2 fusions only
contain the transcription/translation start of ETV6.19,20 These fu-
sions are believed to represent ectopic expression of the transcrip-
tion factors EVI1 and CDX2, which are not normally expressed in
the hematopoietic system. These data clearly illustrate that most
cloned translocations involving ETV6 fit to the paradigm of the
generation of fusion proteins, either chimeric kinases or chimeric
transcription factors. However, the molecular analysis of a t(6;
12)(q23;p13)21 and the recurrent t(5;12)(q31;p13),22 with the 5q31
breakpoints ranging from the 59 end to the 39 end of the long fatty
acyl-CoA synthetase 2 (ACS2) gene (official gene symbol
KIAA0837), has indicated a lack of functionally significant fusion
proteins, suggesting that another mechanism is involved in these
translocations.
We previously described the in-frame fusion of a novel gene,
CHIC2 (BTL), to ETV6 in 1 case of myeloid/natural killer (NK) cell
leukemia and 3 cases of acute myeloid leukemia (AML)-M0 with
a t(4;12)(q11-q12;p13).23 Although we have characterized CHIC2
as a palmitoylated membrane-associated protein,24 its function
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remains unknown and the oncogenic features of CHIC2-ETV6 are
not yet understood. We describe here a further molecular analysis
of the recurrent t(4;12)(q11-q12;p13) based on the characterization
of 2 additional cases. Surprisingly, although the breakpoints in
these cases were located within the region spanned by the P1-based
artificial chromosome (PAC) contig at the CHIC2 locus,23 the
CHIC2-ETV6 fusion was absent and no other meaningful fusions
could be detected. Based on this observation and taking into
account that the recurrent t(5;12)(q31;p13) is also lacking a
functionally significant fusion transcript,22 we hypothesized that
these recurrent translocations may involve the ectopic expression
of protooncogenes at the partner chromosomes. To evaluate this
possibility, the genomic regions telomeric to the breakpoints at
4q11-q12 and 5q31 were investigated for the presence of candidate
protooncogenes, and the expression of the identified candidate
genes was investigated. Our results suggest that ectopic expression
of the homeobox gene GSH2 and the growth factor gene inter-
leukin-3 (IL-3), located close to the breakpoints at 4q11-q12 and
5q31, respectively, may be the underlying leukemogenic factors
explaining the pathogenesis of the t(4;12)(q11-q12;p13) and
t(5;12)(q31;p13).
Patients, materials, and methods
Case reports
Case 1 is a myeloid/NK cell leukemia, and cases 2, 3 and 4 are AML-M0
cases with a t(4;12)(q11-q12;p13), which were previously described.23 Two
additional cases with a t(4;12)(q11-q12;p13) were collected at the Univer-
sity Hospital of Navarra, Spain, (case 5) and the University Hospitals
Leuven, Belgium (case 6). Case 5 (male, age 47) was diagnosed as
AML-M2 and was previously described.6 The material was obtained at
relapse. Case 6 (male, age 25) presented with a de novo acute lymphocytic
leukemia (ALL) at 11 years of age. He received chemotherapy over a period
of 3 years. Fourteen years after the first diagnosis of ALL, he presented with
therapy-related AML. Complete remission was obtained, but the patient
relapsed and died of leukemia 1 year after the diagnosis of AML. Case 7
(male, age 49) was diagnosed as atypical CML (aCML) with karyotype
46,XY, t(5;12)(q31;p13) and was previously described.25 All studies were
performed on bone marrow samples, except for case 3, for which we
obtained a peripheral blood sample containing less than 10% blasts.
RNA isolation and cDNA synthesis
Total RNA was isolated using Trizol (Life Technologies, Paisley, United
Kingdom). Poly(A)1 RNA from control bone marrow, peripheral blood,
and fluorescence-activated cell sorted (FACS) cells was obtained using the
mRNA isolation kit for blood/bone marrow (Roche, Mannheim, Germany).
Poly(A)1 RNA from fetal brain was purchased from Clontech, Palo Alto,
CA. First-strand complementary DNA (cDNA) was prepared from total
RNA or poly(A)1 RNA using Moloney murine leukemia virus reverse
transcriptase (RT) (Life Technologies) and random hexamer primers.
Rapid amplification of cDNA ends
Rapid amplification of cDNA ends (RACE) was performed as previously
described.23 For 59-RACE on case 5, nested polymerase chain reaction
(PCR) was performed using the primers ETV6R3a (59-GAATGAG-
GAGATCGATAGCG-39) and ETV6R3b (59-TCCCTGCTCCAGTAAATT-
GGCTGCAAG-39). For 39-RACE on case 5, nested PCR was performed
using the primers ETV6F1a (59-TGAGACATGTCTGAGACTCCTGCT-
39) and ETV6F2 (59-CCTCCAGAGAGCCCAGTGCCGAGT-39). For 39-
RACE on case 7, nested PCR was performed using the primers ETV6F1a
and ETV6F1b (59-ACTCCTGCTCAGTGTAGCATTAAG-39).
Reverse transcriptase–polymerase chain reaction
Standard RT-PCR was performed to assess the expression of the CHIC2-
ETV6 fusion gene and the expression of IL-3, CSF2, IL-5, and IL-9. The
primers used were IL-3F (59-AACCTGGAGGCATTCAACAG-39) and
IL-3R (59-ACGTCAGTTTCCTCCGGAAT-39), CSF2F (59-AGGATG-
TGGCTGCAGAGC-39) and CSF2R (59-AGGGCAGTGCTGCTTGT-
AGT-39), IL-5F (59-CAAACGCAGAACGTTTCAGA-39) and IL-5R
(59-CAGTACCCCCTTGCACAGTT-39), and IL-9F (59-CCTCTGA-
CAACTGCACCAGA-39) and IL-9R (59-CTTGCCTCTCATCCCTCTCA-
39). TaqMan PCR was performed to analyze the expression of GSH2 using
the TaqMan PCR mix (Perkin Elmer, Wellesley, MA) and 10 pM of the
primers GSH2TMF (59-AGATTCCACTGCCTCACCATG-39), GSH2TMR
(59-TCTCTCTCCAGCTCCAGGAGTT-39), GAPDTMF (59-AGCCTCAA-
GATCATCAGCAATG-39), and GAPDTMR (59-ATGGACTGTGGTCAT-
GAGTCCTT-39) together with 10 pM of the probes GSH2TMP (59-FAM-
CTCTGACGCCAGCCAGGTACCCA-TAMRA-39) and GAPDTMP
(59-JOE-CCAACTGCTTAGCACCCCTGGCC-TAMRA-39). The detec-
tion of GAPD served as internal control. The CT values given in the text
represent the number of the PCR cycle in which the fluorescent signal
significantly exceeds background levels.
Generation of sequence tagged site markers
Sequence tagged sites (STSs) were designed based on available genomic
sequences. The primers used were as follows: for STS-G, 59-GCACCGC-
CACCACCTACAAC-39 and 59-GGGGATGTGAGGGAGGAGGC-39; for
STS-K, 59-AAGCAGGAACTGTGGAAGGTG-39 and 59-GTGGCCAA-
GATAAGGGGCTA-39; for STS-5A, 59-TGGGGTGCACTCTGTACATC-39
and 59-GAACCAGTAGGCAAGGATGG-39; for STS-3A, 59-AAATGTTC-
CCCTGTGTGTGC-39 and 59-CCCATCATTTGTAGGCTGTTG-39; for
STS-I, IL-3F and IL-3R; and for STS-C, CSF2F and 59-ACAGGCCCACAT-
TCTCTCAC-39. PCR was performed with an annealing temperature of
60°C and 30 cycles.
Constructs
The construct murine stem cell virus (MSCV)-GSH2, containing the full
open reading frame of GSH2, was obtained by ligating a genomic fragment
containing exon 1 to a PCR product containing exon 2 using the NcoI
restriction site at the border of the 2 exons into the retroviral vector
MSCV-puromycin (kindly provided by Dr D.G. Gilliland, Harvard, Boston,
MA). The MSCV-GSH2delN construct, containing only the homeobox
domain, and the MSCV-GSH2delH construct, containing the open reading
frame of GSH2 with a deletion in the homeobox domain, were generated by
PCR. The empty MSCV-puromycin vector (MSCV) served as control.
Cell culture, viral vector production, and transduction
The HEK293T and NIH3T3 cell lines were cultured in Dulbecco modified
Eagle medium containing 10% fetal calf serum. NIH3T3 cells were
obtained from the American Tissue Culture Collection (ATCC, Manassas,
VA). Viral vectors were produced by cotransfection of HEK293T cells with
a mixture of the respective MSCV plasmids and an ecotropic packaging
plasmid (Cell Genesys, Foster City, CA) using Fugene-6 (Roche). Transduc-
tion of NIH3T3 cells was performed in 6-well plates in the presence of
polybrene (8 mg/mL) (Sigma, St Louis, MO). After 8 hours, the cells were
washed with phosphate-buffered saline and fresh medium was added. After
24 hours, selection was started using puromycin (3 mg/mL). All experi-
ments were started within 2 weeks after the transduction and were
performed at least in double using independent transductions.
FACS of bone marrow cells
Bone marrow cells were obtained from healthy volunteers. Mononuclear
cells, obtained by using a Ficoll density gradient, were separated in a
CD341 and CD342 fraction by use of the magnetic-activated cell separa-
tion procedure (Miltenyi Biotec, Auburn, CA). Further fractionation was
performed by incubation with the appropriate monoclonal antibodies and
subsequent separation by FACS. The antibodies used were fluorescein
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isothiocyanate– or phycoerythrin-conjugated anti-CD3, anti-CD7, anti-
CD13, anti-CD33, anti-CD34, and anti-CD38 (Becton Dickinson, Franklin
Lakes, NJ).
Genomic clones
PAC clones for the CHIC2 locus were previously described.23 The bacterial
artificial chromosome (BAC) clone 434C1, containing more than 100
kilobases (kb) upstream and 40 kb downstream of exon 1 of ETV6, was
identified by database searches and obtained from the RPCI11 library
(Roswell Park Cancer Institute, Buffalo, NY). Other clones from the ETV6
locus were previously described.26,27 The PAC clones P3701 and P3704
were identified by screening of the RPCI5 library (Roswell Park Cancer
Institute) using a probe derived from the 59 end of the ACS2 gene. The
localization of cosmid c33g8 (kindly provided by Dr M. Lovett) at the IL-3
locus was previously described.28
Results
Molecular cloning of additional t(4;12)(q11;p13) cases
We previously described the molecular analysis of a myeloid/NK
cell leukemia and 3 AML-M0 cases with a t(4;12)(q11-q12;p13).23
All cases were characterized by the presence of a fusion of the first
3 exons of CHIC2 (BTL) to exons 2 to 8 of ETV6 (TEL). For 3 of
these cases, the 4q breakpoint was determined by fluorescence in
situ hybridization (FISH) and mapped to the region spanned by
PAC 1146G14 (Figure 1). For this study, 2 additional AML cases
with a t(4;12)(q11-q12;p13) were collected. Investigation of these
cases by FISH revealed the breakpoints at 12p13 to be located in
intron 2 of ETV6 for case 5 and close to exon 1 (upstream or
downstream of exon 1) of ETV6 for case 6 (Table 1). Unlike the
previously reported cases, for which FISH showed split signals for
PAC 1146G14, the 4q11-q12 breakpoint of case 5 was located
telomeric to PAC 1146G14 and in the region covered by PAC
238H24, while the breakpoint in case 6 was located in the region
spanned by PAC 200D9 and telomeric to PAC 238H24 and thus
upstream of CHIC2 (Table 1, Figure 1). This directly excluded the
presence of a CHIC2-ETV6 fusion in case 6. Attempts to amplify a
CHIC2-ETV6 fusion transcript in case 5 using primers in exon 1 of
CHIC2 and in exon 3 of ETV6 yielded no product, whereas the
control (case 1, previously described23) was positive, indicating
that also in case 5 no CHIC2-ETV6 fusion transcript was present
(results not shown).
We next investigated the presence of other fusion transcripts in
case 5. Using 59-RACE starting from exon 3 of ETV6, transcripts
were detected fusing a novel sequence to exon 2 or directly to exon
3 of ETV6 (Figure 2). This translocation seemed to be complex,
because 39-RACE experiments showed the presence of a transcript
fusing exon 2 of ETV6 to the same sequence as identified by
59-RACE (Figure 2), indicative of a duplication of both 12p and 4q
sequences associated with the translocation. No DNA from this
case was available to confirm this by Southern blotting. Unfortu-
nately, due to lack of sufficient material, a molecular analysis could
not be performed for case 6.
Cloning of human GSH2/HSG2
Database searches revealed 100% identity of part of the sequence
obtained by 59-RACE from case 5 to several human expressed
sequence tags. These represent the GSH2 gene; they are highly
similar to the murine Gsh2 cDNA sequence. However, the se-
quence fused to ETV6 was derived from the complementary
noncoding strand of GSH2. Part of this novel sequence overlapped
with exon 2 of GSH2 and was found to be colinear with the
sequence of BAC AC009614, while the other part of the novel
sequence was found to be colinear with BAC AC069068. Consen-
sus splice donor and acceptor sequences were present at the
genomic sequences, indicating that these 2 parts are 2 exons of a
novel gene that is located at the GSH2 locus but is transcribed in the
opposite direction as GSH2 and hence was named HSG2 (Figure
1). Stop codons were found to be present in the 3 different reading
frames, indicating that these exons are derived from the 59- or
39-untranslated region of HSG2 or that HSG2 is a noncoding
transcript. The exact identity and complete cDNA sequence of
HSG2 was not further analyzed. Because the complete HSG2
transcript is currently unknown, the 2 exons of HSG2 identified in
this work could not be numbered and were named exon j and
exon k.
Next, the 2 exons of GSH2 were cloned from a HindIII fragment
of PAC 200D9. Similar to murine Gsh2, the complete 915 bp open
Figure 1. PAC/BAC contig covering the CHIC2 locus at 4q11-q12 and localiza-
tion of the different breakpoints of the t(4;12)(q11;p13). We previously reported
the generation of a PAC contig (PACs 200D9, 238H24, and 1146G14) spanning the
CHIC2 locus at 4q11-q12.23 Database searches identified several partially se-
quenced BAC clones containing the CHIC2 and GSH2 genes, which were aligned to
the PAC contig (drawing not to scale). Using PCR and database searches, GSH2 and
the 2 exons of HSG2 were located on this contig. The localization of the breakpoints
of 6 t(4;12) cases is indicated by an arrowhead and numbered according to the cases
as described in the text. Exons are represented by open or filled squares, and the
transcriptional orientation is indicated by an arrow. The sequenced BAC clones are
represented by their accession numbers. Tel indicates telomeric side; cen, centro-
meric side; open circle, negative by hybridization or PCR; filled square, positive by
hybridization or PCR; x, positive by electronic PCR/database searches.
Table 1. Summary of the FISH results obtained for the 2 novel
t(4;12)(q11-q12;p13) cases
Probes (Localization) Case 5 Case 6
4q11 CHIC2
200D9 Exon 1 der(12) split or der(12)*
238H24 Exons 1-6 split der(4)
1146G14 Exons 4-6 der(4) der(4)
12p13 ETV6
434C1 Telomeric to exon 1/exon 1 der(4)
209J1 Exon 1/intron 1 der(12)
179A6 Exon 1/intron 1 der(4)
50F4 Intron 1/exon 2 der(4)
TEL11 Intron 2/exon 3 split
54D5 Exons 5-8 der(12)
148B6 Exon 8 der(12) der(12)
*Only part of the metaphases showed split signals. This is indicative for a
breakpoint close to the centromeric side of the region covered by PAC 200D9.
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reading frame of GSH2 was found to be present in 2 exons
(sequence submitted to GenBank), separated by an intron of 2 kb.
Several expressed sequence tags were found to match 100% with
the exon sequences determined by us and confirmed the splice
sites. In addition, RT-PCR on cDNA from human fetal brain using
primers in the different exons confirmed the expression and
splicing of GSH2 (results not shown).
An STS derived for exon 2 of GSH2 (STS-G) and for exon k of
HSG2 (STS-K), respectively, was used to assess their localization
in our PAC contig spanning the CHIC2 locus. GSH2, and thus also
exon j of HSG2, was found to be present only in PAC 200D9,
whereas exon k of HSG2 was located in the region shared between
the PACs 200D9 and 238H24 (Figure 1).
Taken together, these data indicated that GSH2 was located in
front of CHIC2 and that not GSH2, but its antisense gene, HSG2,
was fused to ETV6 in case 5. Because the HSG2 transcript
contained stop codons in all reading frames, no HSG2-ETV6
fusion protein can be generated. Thus, in case 5, no functionally
significant fusion transcript was generated by the translocation.
However, knowing that the GSH2 gene was in close proximity to
the breakpoint in the t(4;12)(q11-q12;p13) cases and taking into
account that ectopic expression of homeobox genes is a known
mechanism involved in leukemia, we hypothesized that ectopic
expression of GSH2 could represent an alternative leukemogenic
event. To investigate this, we analyzed the expression of GSH2 in
these cases and investigated its transforming properties using a
focus formation assay in the NIH3T3 cell line.
Expression of GSH2 in the t(4;12)
We analyzed the expression of GSH2 by use of TaqMan real-time
quantitative RT-PCR using GAPD as an internal control. As
expected, expression of GSH2 was detected in control cDNA
derived from fetal brain. No expression was detected in any of the
hematopoietic tissues analyzed or in the myeloid cell line HL60.
However, expression of GSH2 was detected in the 4 cases that we
previously described to contain the CHIC2-ETV6 fusion (cases
1-4) and in the AML-M2 case (case 5), which contains the
HSG2-ETV6 fusion but lacks the CHIC2-ETV6 fusion (Table 2).
Although the CT value for GSH2 in case 5 was rather high, this was
still different from the negative control samples. RNA from this
case was extracted from fixed cells and was of poor quality, as is
also clear from the higher CT value for GAPD. To exclude that the
expression of GSH2 detected in these cases was the result of a
clonal expansion of a CD341 cell type expressing GSH2, we also
analyzed the expression of GSH2 in CD341 fractions of bone
marrow that was highly enriched for the respective markers (Table
1). Expression of GSH2 could not be detected in any of these
subpopulations. Both GAPD (Table 1) and the expression of the
Figure 2. RACE results for case 5 indicating the different HSG2-ETV6 and
ETV6-HSG2 fusions. The 59- and 39-RACE, performed on cDNA obtained from case
5, revealed the existence of 3 different HSG2-ETV6 fusion transcripts and an
ETV6-HSG2 fusion transcript. Exon 2 of ETV6 and exon k of HSG2 are present in
both types of fusions, which can only be explained by a duplication event associated
with the translocation. Exon k of HSG2 is underlined; sequences from ETV6 are in
italics; stop codons are in bold.
Table 2. TaqMan real-time quantitative RT-PCR analysis of the expression
of GSH2
Sample
CT value*
DCTGAPD GSH2
Fetal brain 15.5 26.0 10.5
Bone marrow 19.6 6 0.2 Greater than 40 No expression
Peripheral blood 23.4 6 0.2 Greater than 40 No expression
Spleen 22.6 6 0.3 Greater than 40 No expression
HL60 cell line 16.0 6 0.4 Greater than 40 No expression
CD341 21.1 6 0.9 Greater than 40 No expression
CD341CD382 33.3 6 0.6 Greater than 40 No expression
CD341CD381 24.5 6 1.3 Greater than 40 No expression
CD341CD71 26.4 6 0.2 Greater than 40 No expression
CD341CD131CD331 23.2 6 0.5 Greater than 40 No expression
CD342 18.0 6 1.0 Greater than 40 No expression
CD342CD31 27.3 6 0.6 Greater than 40 No expression
CD342CD131 30.3 6 0.6 Greater than 40 No expression
CD342CD331 27.7 6 1.2 Greater than 40 No expression
BM from case 1 22.7 25.4 3.3 6 0.8
BM from case 2 24.9 30.3 5.7 6 0.3
PB from case 3 25.0 33.8 9.6 6 0.7
BM from case 4 22.2 26.9 4.2 6 0.7
BM from case 5† 28.3 37.1 9.0 6 0.5
BM from case 6 Nd nd nd
Water‡ Greater than 40 Greater than 40 No expression
*The CT value was determined in at least 3 independent experiments. It is
indicated as mean 6 SD when no expression of GSH2 was detected. When
expression of GSH2 was detected, individual CT values are given from 1 representa-
tive experiment and the mean 6 SD is determined from the DCT values obtained from
the independent experiments.
†RNA was extracted from fixed cells.
‡Water was used as “no template control” in each experiment.
Table 3. Summary of the focus formation experiment
Construct Number of foci
MSCV-GSH2 Greater than 200
MSCV-GSH2-delN 15-35
MSCV-GSH2-delH 0-10
MSCV 0-10
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homeobox gene NKX2-3 (data not shown) were easily detected,
indicating that the negative result for GSH2 was not due to a
technical problem and that the RNA extraction from these FACS-
sorted cells was adequate.
Overexpression of GSH2 transforms NIH3T3 cells
To investigate the transforming properties of GSH2 in vitro, we
retrovirally transduced the NIH3T3 cell line with the empty MSCV
vector or with the MSCV vector containing wild-type GSH2
(MSCV-GSH2), GSH2 with a deletion of the N-terminus (MSCV-
GSH2delN), or GSH2 with a deletion of the homeobox domain
(MSCV-GSH2delH), respectively. Focus formation was deter-
mined as the ability to induce a significant larger number of foci
than observed after transduction of the empty vector. Experiments
with the different constructs were performed at the same time, with
the same batch of cells. The number of spontaneous foci observed
for the empty vector was 10 at maximum. In contrast, overexpres-
sion of wild-type GSH2 resulted in the presence of more than 200
small foci per 10 cm dish (Figure 3A,B, Table 2). The deletion
mutants of GSH2 induced only a small number of foci, comparable
to the empty vector (Table 3). Typically, these foci were larger in
size than the foci induced by overexpression of GSH2 (Figure 3D),
although microscopically the foci induced by GSH2 were clearly
composed of transformed cells but apparently grew more slowly
(Figure 3GH). We also tested whether expression of the CHIC2-
ETV6 fusion (MSCV-CHIC2ETV6) had transforming properties,
but expression of CHIC2-ETV6 did not induce focus formation in
the NIH3T3 cell line (results not shown).
Molecular analysis of an atypical CML case with a
t(5;12)(q31;p13)
The t(5;12)(q31;p13) has been described as a recurrent trans-
location occurring in various myeloid malignancies (at least 18
cases were previously described), often associated with eosino-
philia.22,25,29-32 We collected an atypical CML (aCML) case with a
t(5;12)(q31;p13) as the sole chromosomal abnormality and investi-
gated the presence of a possible fusion transcript. This case was
described previously, and the breakpoint in ETV6 was mapped to
intron 1.25 RACE experiments revealed the presence of an ETV6-
ACS2 fusion, confirming that this case was similar to the cases
reported by Yagasaki et al.22 Further analysis by RT-PCR revealed
the presence of 3 different ETV6-ACS2 fusion transcripts, among
which was an in-frame fusion fusing the first 11 amino acids of
ETV6 to almost the complete ACS2 protein (Figure 4). According
to the RT-PCR results, the breakpoint in ACS2 was at the 59 end of
this gene, similar to case 3 described by Yagasaki and coworkers.22
However, in the 3 cases studied by Yagasaki and colleagues,
only out-of-frame ETV6-ACS2 fusion transcripts were identified,
showing that the t(5;12)(q31;p13) does not generate a common
in-frame fusion gene. The exact leukemogenic factor responsible
for the pathogenesis of the t(5;12)(q31;p13) thus remained unre-
solved. According to these observations, the only invariant result of
this translocation is the juxtaposition of the region directly
telomeric to ACS2 with the ETV6 locus. We therefore investigated
whether this could lead to the juxtaposition of a protooncogene on
5q31 to ETV6 and if this could better explain the leukemogenic
mechanism of this translocation.
Analysis of the region telomeric to the breakpoint at 5q31
revealed the presence of the IL-3/CSF2 locus in the genomic
sequence of BAC CTD-2198K16 (accession no. AC034228) that
also contained the 59 end of ACS2. This was confirmed by further
analysis of this region using the available genomic sequences
(accession numbers are listed in Figure 5) and by mapping of 2
PAC clones (P3701 and P3704) and a cosmid (c33g8) by PCR
using STS markers specific for the 59 end of ACS2 (STS-5A) and
the 39 end of ACS2 (STS-3A), IL-3 (STS-I), and CSF2 (STS-C)
(Figure 5). A complete 1 Mb contig encompassing the ACS2, IL-3,
CSF2, IRF1, IL-5, and IL-4 loci was constructed previously,33
although the exact orientation of this contig remained unclear. This
was due mainly to the small physical distance between the IL-3 and
IL-5 loci, which made FISH-based mapping difficult and resulted
in contradictions in the literature.28,34 The cloning of 4 t(5;12) cases
with an ETV6-ACS2 fusion and the known telomere to centromere
orientation of ETV626 are strongly suggestive for a telomere to
centromere orientation of ACS2, enabling orientation of the contig
described by Frazer et al33 as centromere–ACS2–IL3– CSF2–IRF1–
IL5–IL4–telomere. In agreement with this, Yagasaki et al22 mapped
the IRF1 gene telomeric to the 5q31 breakpoint by FISH, and
Grimaldi et al35 cloned the t(5;14)(q31;q32) breakpoint, also
confirming that CSF2 is located telomeric to IL-3. Taken together,
all these data are consistent with a localization of IL-3 immediately
telomeric to ACS2, as shown in Figure 5. Because ACS2 and IL-3
were both present in PAC P3704 and according to the contig
Figure 3. Focus formation assay illustrating the oncogenic potential of GSH2.
Monolayer of cells overexpressing wild-type GSH2 (A,B: 2 different frames of the
same dish), indicating a high number (. 200 foci/10 cm dish) of relatively small foci,
compared with the monolayer of cells transduced with the empty MSCV vector (C). In
the latter case, spontanous foci (0-10 foci/10 cm dish) were observed. Typically, these
foci were relatively larger than the foci observed with GSH2 overexpression (compare
panels A and B with D). The N-terminal deletion mutant and homeobox deletion
mutant of GSH2 induced only a low number of foci, similar to the empty vector. The
monolayers observed with these construct are shown in panels E and F. (A-F: scale
bar 5 2 mm). The morphology and size of the foci observed for these constructs were
similar to the foci observed for the empty vector. Although the cells overexpressing
GSH2 generated relatively small foci, higher-magnification pictures (G,H) clearly
show the presence of transformed cells growing on top of the monolayer.
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reported by Frazer et al,33 the distance between these genes is most
probably 100 kb or less.
Expression of IL-3 in the t(5;12)(q31;p13)
The expression of IL-3, CSF2, IL-5, and IL-9 was analyzed in a
bone marrow sample obtained from the aCML case (case 7). Only
expression of IL-3 could be clearly detected (Figure 6), indicating a
good correlation between the position of the breakpoint and the
expression of IL-3 in this myeloid sample. Although CSF2 is only
10 kb distal to IL-3, no expression of this gene was observed. The
expression of IL-5 and IL-9, which are not located in the immediate
surroundings of the t(5;12) breakpoint, was investigated as a
control. In this way a “contamination” of the sample with normal T
cells expressing IL-3 was excluded because expression of IL-5 and
IL-9 would then also be detected.
Discussion
We report here a further molecular study of the recurrent transloca-
tions t(4;12)(q11-q12;p13) and t(5;12)(q31;p13). Our results de-
scribed in this work together with our previous study23 and the
study of Yagasaki and colleagues22 clearly indicate heterogeneity in
the localization of the breakpoints at both 4q11-q12 (upstream, at
the 59 end or in intron 3 of CHIC2) and 5q31 (at the 59 end, in the
middle or at the 39 end of ACS2). In correspondence with this, no
common fusion transcript that could explain the pathogenic
character of these translocations is generated by either of these
translocations. In addition, the HSG2-ETV6 transcript detected in
case 5 with the t(4;12) and the ETV6-ACS2 transcripts described by
Yagasaki et al22 in cases with a t(5;12) do not represent in-frame
fusion transcripts, raising the question as to how these transcripts
contribute to the pathogenesis of the respective translocations. Two
other AML cases with a t(4;12)(q11-q12;p13) and an HSG2-ETV6
fusion have been reported,36 further confirming the heterogeneity
of the 4q11-q12 breakpoints.
In fact, the only invariant result of these translocations is the
juxtaposition of the chromosomal regions telomeric, respectively,
to CHIC2 on 4q11-q12 and ACS2 on 5q31 to the ETV6 locus on
Figure 4. Detection of ETV6-ACS2 fusion transcripts in the aCML case with a
t(5;12)(q31;p13) (case 7). (Ai) RT-PCR confirmed the fusion of ETV6 to ACS2, as
identified by 39-RACE in the t(5;12) case (case 7). (Aii) Hybridization with an internal
oligonucleotide revealed the existence of 3 different fusion transcripts, which was
confirmed by cloning and sequencing of these RT-PCR products, shown in the lower
panel. (B) Representation of the identified fusion transcripts. Open reading frames
were determined on the basis of the start codon of ETV6. Only transcript C is an
in-frame fusion. Exon numbering of ACS2 is according to Yagasaki et al.22
Figure 5. PAC/BAC/cosmid contig covering the ACS2 and IL-3/CSF2 loci at
5q31 and localization of the different breakpoints of the t(5;12)(q31;p13).
Schematic illustration of the small PAC/cosmid contig linking ACS2 with IL-3/CSF2
(not to scale). Database searches identified several partially or completely se-
quenced genomic clones containing the ACS2, IL-3, CSF2, and P4HA2 genes,
confirming the PAC contig. These clones are represented by their accession
numbers. Yagasaki et al22 mapped IRF1 telomeric to the breakpoints of the t(5;12). A
1 Mb contig was previously described33 that links ACS2 to IL-5 and is in agreement
with the map shown here. The 3 t(5;12)(q31;p13) breakpoints described by Yagasaki
et al22 are numbered as Y1, Y2, and Y3. The breakpoint described in this work is
indicated with case 7, as described in the text. Genes are represented by boxes, and
their transcriptional orientation is indicated by an arrow. The sequenced BAC clones
are represented by their accession numbers. tel indicates telomeric side; cen,
centromeric side; open circle, negative by hybridization or PCR; filled square, positive
by hybridization or PCR; x, positive by electronic PCR/database searches.
Figure 6. Expression of IL-3 in the aCML case with a t(5;12)(q31;p13) (case 7).
Expression of IL-3 but not of CSF2, IL-5, or IL-9 was detected in a bone marrow
sample from the patient with aCML (case 7). By contrast, high-level expression of IL-3
could not be detected in control bone marrow cells (BM), indicating ectopic
expression of IL-3 in the t(5;12) case. The faint band observed at 394 bp in control
bone marrow is due to a genomic contamination of the RNA sample.
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12p13. The juxtaposition of protooncogenes to the RPN1 locus, the
IgH/L loci, or the TCR loci has been well illustrated and results in
the deregulated expression of these protooncogenes.2,3,37 We identi-
fied the homeobox gene GSH2 and the growth factor genes IL-3
and CSF2 in the regions adjacent to the breakpoints at, respectively,
4q11-q12 and 5q31 of the t(4;12)(q11-q12;p13) and the t(5;12)(q31;
p13). Ectopic expression of GSH2 was detected in all t(4;12)(q11;
p13) cases, with or without the CHIC2-ETV6 fusion, and expres-
sion of IL-3 was observed in the aCML case with a t(5;12)(q31;
p13), also characterized by an ETV6-ACS2 fusion. These results
suggest that ectopic expression of GSH2 and IL-3 could be the
underlying leukemogenic mechanisms of the t(4;12)(q11-q12;p13)
and t(5;12)(q31;p13) cases, independent of the presence of fusion
transcripts.
The Gsh2 gene was previously characterized as a brain-specific
homeobox gene important in forebrain and hindbrain formation
of the mouse.38,39 We did not find evidence that GSH2 is also
expressed during hematopoiesis. Interestingly, GSH2, belonging
to the ParaHox genes,40 contains a homeobox domain that is
very similar to the homeobox of the clustered HOX genes,
which are involved in both normal and abnormal hematopoi-
esis.41 In addition, overexpression of GSH2 was found to induce
focus formation in the NIH3T3 cell line (Figure 3), illustrating
its oncogenic potential.
Evidence for the involvement of IL-3 in leukemia was described
previously by the analysis of the t(5;14)(q31;q32) in B-ALL,
involving ectopic expression of IL-3 as a consequence of its
translocation to the IgH locus,35,42 and by analysis of mutations
found in the murine WEHI-3B cell line, which illustrated that
ectopic expression of HoxB8 and IL-3 together results in AML in a
mouse model.43 Although expression of IL-3 alone produced only a
nonneoplastic myeloproliferative disease in this mouse model, it is
clear from these studies that ectopic expression of IL-3/IL-3 leads
to a proliferative defect and may be involved in the multistep
process of leukemogenesis.43,44 In addition, because IL-3 is a
growth factor regulating eosinophil proliferation and differenta-
tion,45 ectopic expression of IL-3 could also explain the eosino-
philia associated with the t(5;12) cases,22,25,29-32 as was also
observed for the t(5;14)(q31;q32).35,42 This is supported by the
observation that continuous administration of IL-3 leads to a dose-
and time-dependent eosinophilia.46
Although we clearly detected expression of GSH2 and IL-3 in
the t(4;12) and t(5;12) cases, several remarks must be taken under
consideration when describing this as an abnormal expression.
Bone marrow is a heterogeneous mixture of different cell types of
which in leukemia only one particular cell was originally mutated
and expanded. It is thus possible that the expression of a gene,
which is expressed only in a rare bone marrow cell type, would
become detectable by RT-PCR in leukemic bone marrow as a
consequence of the clonal expansion of this cell type. Second,
translocations are known to occur in open chromatin structures,
suggesting that the genes found at the breakpoints are transcription-
ally active, thus arguing that the detected expression of GSH2 and
IL-3 in the leukemias might not be abnormal. However, the
breakpoints of the t(4;12) and t(5;12) are not very close to GSH2 or
IL-3 but occur in or at least close to, respectively, the CHIC2 and
ACS2 genes, which are expressed in the hematopoietic system22,23
and thus most probably are located in an open chromatine region,
providing space for the translocations to occur. The fact that GSH2
expression could not be detected in any of the analyzed subpopula-
tions highly enriched for CD341 cells further indicates that GSH2
is not expressed in the hematopoietic system, although we cannot
exclude its expression in a particularly rare bone marrow cell type.
However, even if GSH2 would be expressed in a rare bone marrow
cell type that escaped our detection, this would not directly exclude
GSH2 from its involvement in the t(4;12). Transformation might
then be the result of the inability to down-regulate GSH2, rather
than its induced expression. In this regard, the ectopic expression of
Hoxa9 by retroviral insertion in BXH2 mice is a well-characterized
example illustrating that the ectopic expression of a gene that is
normally expressed in bone marrow progenitor cells can neverthe-
less be leukemogenic.47,48
It has been well established that IL-3 is expressed by activated T
cells, NK cells, and mast cells.49 Detection of its expression in a
CML sample, containing mainly myeloid cells, is suggestive for its
abnormal expression in this cell type. If expression of IL-3 would
be the result of the presence of other IL-3–producing cells, then
expression of other growth factors such as CSF2, IL-5, and IL-9
also would be expected, which was not the case (Figure 6).
Although IL-3 and CSF2 are located very close to each other, no
expression of CSF2 was detected in the aCML case (Figure 6).
Interestingly, this was also observed in B-cell ALL cases with a
t(5;14)(q31;q32) involving the IgH locus.42 Although IL-3 and
CSF2 have an overlapping expression pattern, CSF2 expression
can also be regulated separately.49,50 Elucidation of the mechanism
by which expression of IL-3 becomes activated in these leukemias
could provide further explanation for this.
The exact mechanism by which expression of GSH2 and IL-3 is
activated is currently not known. It has become clear that the final
transcription level of a gene is determined by the combined action
of regulatory sequences that might be either positive or negative
and the accessibility of these sequences determined by the chroma-
tin structure and the nuclear architecture.51,52 Therefore, it might be
expected that regulatory sequences as enhancers in ETV6 and
silencers at the partner chromosome can be major contributors,
with additional effects from the change in chromatin structure
around the breakpoint. Well-known examples involving enhancer-
mediated ectopic expression are the translocations involving the
RPN1 locus, the IgH/L loci, or the TCR loci.2,3,37,53 These studies
have also clearly illustrated that the breakpoints can be located up
to 200 kb away from the deregulated protooncogene.3 Other
examples of how translocations can influence the expression of
genes have been described for the translocations associated with
Beckwith-Wiedemann syndrome, which involve aberrant expres-
sion of the IGF2 gene by loss of imprinting,54,55 and for chromo-
some rearrangements at the Kit/Pdgfra loci in mutant mice,
affecting the expression of Kit.55,56 In addition to the effects of
enhancers and silencers, all translocations are likely to change local
chromatin structure and nuclear architecture in its whole, which
may be associated with changes in gene expression.
Taken together, our results indicate that the common mecha-
nism of the t(4;12)(q11-q12;p13) cases, with or without the
CHIC2-ETV6 fusion, may be the ectopic expression of GSH2.
Further analysis of additional cases with breakpoints at the 59 end
of CHIC2 and analysis of the in vivo leukemogenic properties of
GSH2 will be necessary to fully understand the importance of its
expression in the t(4;12)(q11-q12;p13) cases. In addition, our
results suggest that the AML-M0 cases represent a subgroup in the
t(4;12)(q11-q12;p13) characterized by both the expression of
GSH2 and the CHIC2-ETV6 fusion. Although expression of
CHIC2-ETV6 does not transform the NIH3T3 cell line, it will be of
interest to investigate whether the presence of the CHIC2-ETV6
fusion plays an additional role in determining the immature
phenotype of the AML-M0 cases. With respect to the reported
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t(5;12)(q31;p13) cases, both our data and the known leukemia-
related properties of IL-3 are supportive for the ectopic expression
of IL-3 as an important transforming mechanism in these cases.
Although we have only been able to investigate a single case, the 3
cases described by Yagasaki et al22 also involve a translocation of
IL-3 to the der,12 supporting the possibility of IL-3–induced
expression by ETV6 regulatory sequences.
Although many translocations involving ETV6 have been
shown to result in the generation of an in-frame fusion gene,
encoding a fusion protein with oncogenic properties, our results
indicated the importance of a variant mechanism: the ectopic
expression of a protooncogene. Other translocations, such as the
reported t(6;12)(q23;p13)21 and t(7;12)(p15;p13)57 and the t(10;
12)(q24;p13) and t(12;13)(p13;q12) (P. M., unpublished results,
2001), seem not to result in the generation of functionally
significant fusion genes. It will be of further interest to investigate
whether these cases involve ectopic expression of a protooncogene.
Interestingly, several cases of the t(3;12)(q26;p13) have been
described, with the 3q26 breakpoints either 59 or 39 to EVI1, a gene
that is ectopically expressed in myeloid malignancies with the inv
(3)(q21q26) or the t(3;3)(q21;q26). One of the t(3;12)(q26;p13)
cases was cloned and revealed the fusion of ETV6 to MDS1/EVI1.19
However, at least one of the other cases described by Raynaud et
al58 had breakpoints centromeric to EVI1 and thus could involve
ectopic expression of EVI1 by a similar mechanism as proposed in
this work. Identification of candidate protooncogenes for other
translocations involving breakpoints at the 59 end of ETV6 will be
greatly facilitated by the availability of the complete human
genome sequence.
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